No Data
Nurix Therapeutics Analyst Ratings
Wells Fargo Maintains Nurix Therapeutics(NRIX.US) With Buy Rating, Maintains Target Price $32
H.C. Wainwright Maintains Nurix Therapeutics(NRIX.US) With Buy Rating, Raises Target Price to $30
Promising Prospects for Nurix Therapeutics: Buy Rating Backed by Strong Data on NX-5948
Nurix Therapeutics Presents Positive Results From the Ongoing Clinical Trial of Its BTK Degrader NX-5948 in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia
Express News | Nurix Therapeutics Expands Its Board of Directors With the Addition of Drug Commercialization Expert Anil Kapur